Purchase of pre-funded warrants and common warrants in the May 2024 registered direct offering
| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Richard A. Miller
Also a director
President, Chief Executive Officer and Chairman of the Board
|
75 | Not stated | Not stated | |
|
Leiv Lea
Chief Financial Officer
|
72 |
Since 2014
12 years
|
Not stated | |
|
Jeffrey S. Arcara
Senior Vice President, Chief Business Officer
|
57 | Not stated | Not stated | |
|
William B. Jones
Senior Vice President, Pharmaceutical Development
|
61 |
Since 2019
7 years
|
2014 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 24, 2026 · updated by the 8-K of Jul 22, 2026
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Purchase of pre-funded warrants and common warrants in the May 2024 registered direct offering
Purchase of shares and common warrants in the May 2024 registered direct offering
Purchase of shares and common warrants in the May 2024 registered direct offering
Purchase of shares and common warrants in the May 2024 registered direct offering
Loading...